Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Summary

The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC). This study will be conducted in Asian patients who are classified as 'never smoker' since it is suggested that these patients are more likely to respond favorably to treatment with gefitinib.

Timeline

Start

2007-02

Primary completion

2009-08

Completion

2010-05

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Pemetrexed/Cisplatin/Gefitinib vs Pemetrexed/Cisplatin; p = 0.0618; Log Rank NCT00409006 ↗

Publications

• Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23.

Drugs

Indications